Journal
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
Volume 35, Issue 6, Pages 711-714Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/JCP.0000000000000412
Keywords
antipsychotic-related akathisia; low-dose mirtazapine; serotonin 2A receptor antagonism
Categories
Ask authors/readers for more resources
Akathisia remains a prevalent, clinically significant, and therapeutically challenging adverse event associated with antipsychotic treatment. Compelling evidence supports therapeutic efficacy and clinical utility of agents with marked serotonin 2A receptor antagonism, primarily low-dose mirtazapine, as an effective and well-tolerated antiakathisia treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available